Carlo R Bartoli1, Samson Hennessy-Strahs2, Jeff Gohean3, Maryann Villeda2, Erik Larson3, Raul Longoria4, Mark Kurusz3, Michael A Acker2, Richard Smalling5. 1. Division of Cardiovascular Surgery, Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: carlo.bartoli@uphs.upenn.edu. 2. Division of Cardiovascular Surgery, Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. 3. Windmill Cardiovascular Systems, Inc, Austin, Texas. 4. Windmill Cardiovascular Systems, Inc, Austin, Texas; Department of Mechanical Engineering, The University of Texas at Austin, Austin, Texas. 5. Windmill Cardiovascular Systems, Inc, Austin, Texas; Division of Cardiovascular Medicine, Department of Medicine, University of Texas Health Center, McGovern Medical School, Houston, Texas.
Abstract
BACKGROUND: Continuous-flow left ventricular assist devices (LVADs) cause blood trauma that includes von Willebrand factor degradation, platelet activation, and subclinical hemolysis. Blood trauma contributes to bleeding, thrombosis, and stroke, which cause significant morbidity and mortality. The TORVAD (Windmill Cardiovascular Systems, Inc, Austin, TX) is a first-of-its kind, toroidal-flow LVAD designed to minimize blood trauma. We tested the hypothesis that the TORVAD causes less blood trauma than the HeartMate II (Abbott Laboratories, Pleasanton, CA) LVAD. METHODS: Whole human blood was circulated for 6 hours in ex vivo circulatory loops with a HeartMate II (n = 8; 10,000 rpm, 70 ± 6 mm Hg, 4.0 ± 0.1 L/min) or TORVAD (n = 6; 144 rpm, 72 ± 0.0 mm Hg, 4.3 ± 0.0 L/min). von Willebrand factor degradation was quantified with electrophoresis and immunoblotting. Platelet activation was quantified by cluster of differentiation (CD) 41/61 enzyme-linked immunosorbent assay (ELISA). Hemolysis was quantified by plasma free hemoglobin ELISA. RESULTS: The TORVAD caused significantly less degradation of high-molecular-weight von Willebrand factor multimers (-10% ± 1% vs -21% ± 1%, p < 0.0001), accumulation of low-molecular-weight von Willebrand factor multimers (22% ± 2% vs 45% ± 2%, p < 0.0001), and accumulation of von Willebrand factor degradation fragments (7% ± 1% vs 25% ± 6%, p < 0.05) than the HeartMate II. The TORVAD did not activate platelets, whereas the HeartMate II caused significant platelet activation (CD 41/61: 645 ± 20 ng/mL vs 1,581 ± 150 ng/mL, p < 0.001; normal human CD 41/61, 593 ng/mL; range, 400 to 800 ng/mL). Similarly, the TORVAD caused minimal hemolysis, whereas the HeartMate II caused significant hemolysis (plasma free hemoglobin: 11 ± 2 vs 109 ± 10 mg/dL, p < 0.0001; normal human plasma free hemoglobin <4 mg/dL). CONCLUSIONS: The TORVAD design, with markedly lower shear stress and pulsatile flow, caused significantly less blood trauma than the HeartMate II. LVADs with reduced blood trauma are likely to improve clinical outcomes and expand LVAD therapy into patients with less advanced heart failure.
BACKGROUND: Continuous-flow left ventricular assist devices (LVADs) cause blood trauma that includes von Willebrand factor degradation, platelet activation, and subclinical hemolysis. Blood trauma contributes to bleeding, thrombosis, and stroke, which cause significant morbidity and mortality. The TORVAD (Windmill Cardiovascular Systems, Inc, Austin, TX) is a first-of-its kind, toroidal-flow LVAD designed to minimize blood trauma. We tested the hypothesis that the TORVAD causes less blood trauma than the HeartMate II (Abbott Laboratories, Pleasanton, CA) LVAD. METHODS: Whole human blood was circulated for 6 hours in ex vivo circulatory loops with a HeartMate II (n = 8; 10,000 rpm, 70 ± 6 mm Hg, 4.0 ± 0.1 L/min) or TORVAD (n = 6; 144 rpm, 72 ± 0.0 mm Hg, 4.3 ± 0.0 L/min). von Willebrand factor degradation was quantified with electrophoresis and immunoblotting. Platelet activation was quantified by cluster of differentiation (CD) 41/61 enzyme-linked immunosorbent assay (ELISA). Hemolysis was quantified by plasma free hemoglobin ELISA. RESULTS: The TORVAD caused significantly less degradation of high-molecular-weight von Willebrand factor multimers (-10% ± 1% vs -21% ± 1%, p < 0.0001), accumulation of low-molecular-weight von Willebrand factor multimers (22% ± 2% vs 45% ± 2%, p < 0.0001), and accumulation of von Willebrand factor degradation fragments (7% ± 1% vs 25% ± 6%, p < 0.05) than the HeartMate II. The TORVAD did not activate platelets, whereas the HeartMate II caused significant platelet activation (CD 41/61: 645 ± 20 ng/mL vs 1,581 ± 150 ng/mL, p < 0.001; normal human CD 41/61, 593 ng/mL; range, 400 to 800 ng/mL). Similarly, the TORVAD caused minimal hemolysis, whereas the HeartMate II caused significant hemolysis (plasma free hemoglobin: 11 ± 2 vs 109 ± 10 mg/dL, p < 0.0001; normal human plasma free hemoglobin <4 mg/dL). CONCLUSIONS: The TORVAD design, with markedly lower shear stress and pulsatile flow, caused significantly less blood trauma than the HeartMate II. LVADs with reduced blood trauma are likely to improve clinical outcomes and expand LVAD therapy into patients with less advanced heart failure.
Authors: Zengsheng Chen; Nandan K Mondal; Shirong Zheng; Steven C Koenig; Mark S Slaughter; Bartley P Griffith; Zhongjun J Wu Journal: Platelets Date: 2017-11-28 Impact factor: 3.862
Authors: Carlo R Bartoli; David Zhang; Jooeun Kang; Samson Hennessy-Strahs; David Restle; Jessica Howard; Gretchen Redline; Christian Bermudez; Pavan Atluri; Michael A Acker Journal: Ann Thorac Surg Date: 2017-09-21 Impact factor: 4.330
Authors: Jeffrey R Gohean; Erik R Larson; Brian H Hsi; Mark Kurusz; Richard W Smalling; Raul G Longoria Journal: ASAIO J Date: 2017 Mar/Apr Impact factor: 2.872
Authors: Phat L Tran; Maria-Grazia Pietropaolo; Lorenzo Valerio; William Brengle; Raymond K Wong; Toshinobu Kazui; Zain I Khalpey; Alberto Redaelli; Jawaad Sheriff; Danny Bluestein; Marvin J Slepian Journal: Perfusion Date: 2015-11-20 Impact factor: 1.972
Authors: Anna L Meyer; Doris Malehsa; Ulrich Budde; Christoph Bara; Axel Haverich; Martin Strueber Journal: JACC Heart Fail Date: 2014-04 Impact factor: 12.035
Authors: Carlo R Bartoli; Jooeun Kang; David Zhang; Jessica Howard; Michael Acker; Pavan Atluri; Tadashi Motomura Journal: Ann Thorac Surg Date: 2016-10-04 Impact factor: 4.330
Authors: Callie Frey; Antigoni G Koliopoulou; Emilie Montenont; Neal D Tolley; Hadi Javan; Stephen H McKellar; Stavros G Drakos; Craig H Selzman; Matthew T Rondina Journal: Platelets Date: 2020-01-14 Impact factor: 3.862